

Alisertib

Catalog No: tcsc0106



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg



Specifications

CAS No:

1028486-01-2

Formula:

$C_{27}H_{20}ClFN_4O_4$

Pathway:

Cell Cycle/DNA Damage;Epigenetics;Autophagy

Target:

Aurora Kinase;Aurora Kinase;Autophagy

Purity / Grade:

>98%

Solubility:

DMSO : 9.33 mg/mL (17.98 mM; Need ultrasonic and warming)

Alternative Names:

MLN 8237

Observed Molecular Weight:

518.92


Product Description

Alisertib (MLN 8237) is a selective **Aurora A** inhibitor with an **IC₅₀** of 1.2 nM.

IC50 & Target: IC50: 1.2 nM (Aurora A)^[3]

In Vitro: Alisertib leads the MM cells to mitotic spindle abnormalities, mitotic accumulation, as well as inhibition of cell proliferation through apoptosis and senescence. Alisertib up-regulates p53 and tumor suppressor genes p21 and p27^[1]. The decreased activity of MLN8054/Alisertib for the T217D/W277E Aurora A/TPX2 complex may reflect the increased affinity for ATP induced by cofactor binding to Aurora A^[2]. Alisertib inhibits cell proliferation with IC₅₀ values ranging from 15 to 469 nM in different tumor cell lines^[3].

In Vivo: Alisertib (Alisertib, 30 mg/kg, p.o.) significantly reduces tumor burden and increases overall survival in xenograft-murine model of human-MM^[1]. Alisertib (20, 30 mg/kg, p.o.) causes tumor growth inhibition in solid tumor xenograft models and regressions in in vivo models of lymphoma, and reduces FLT uptake in HCT-116 xenograft tumors^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!